Trogenix Raises £70 Million ($95 Million) In Series A To Advance Clinical Development Of Potentially Curative Cancer Therapies

Trogenix Ltd, a pioneering biotech company focused on developing innovative cancer therapies, has successfully closed its Series A financing round, raising £70 million ($95 million). The funds will accelerate the clinical advancement of Trogenix’s pipeline of potentially curative therapies for multiple aggressive solid tumours, enabling rapid progress toward delivering transformative treatments to patients in need.

Ken Macnamara, Chief Executive Officer of Trogenix, stated that the investment will drive forward the company’s lead programme in glioblastoma and its follow-on programme in colorectal cancer liver metastases, while also advancing research in liver and lung cancers and further enhancing its proprietary Odysseus® platform. He emphasized the company’s mission to deliver breakthrough treatments and potential cures for thousands of patients and families facing devastating cancer diagnoses each year.

The Series A round was led by IQ Capital, with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons and the Brain Tumor Investment Fund, and new investors including Eli Lilly and Company, Meltwind, LongeVC, Calculus Capital, and undisclosed private investors. The funding highlights the transformative potential of Trogenix’s precision genetic medicines, which leverage the Odysseus® platform to target universal vulnerabilities in solid tumours. Trogenix’s technology delivers highly potent combination payloads that selectively kill cancer cells while stimulating the immune system, minimizing damage to healthy tissue and offering a new treatment paradigm for patients.

Max Bautin, Co-founder and Managing Partner at IQ Capital, remarked that the investment reflects confidence in Trogenix’s world-class science, strong management team, and clear clinical and commercial roadmap. He highlighted the company’s promising pipeline and the potential for impactful future collaboration. Cancer Research Horizons also described the investment as its largest to date, demonstrating the organization’s commitment to supporting breakthrough science with the potential to transform cancer care. CEO Iain Foulkes emphasized the significance of Trogenix’s platform as it moves toward clinical trials for glioblastoma, one of the most challenging cancers to treat.

Dima Kuzmin, Co-founder and Managing Partner at 4BIO Capital and Chairman of Trogenix, highlighted the company’s successful journey from initial incubation and spin-out from the University of Edinburgh to its current stage of clinical development, praising the strong investor syndicate and Trogenix’s progress in building a pioneering portfolio of cancer therapies.

Trogenix’s approach combines cancer cell killing with immune system stimulation, employing a “Trojan Horse” strategy to reawaken immune responses and provide long-term protection against tumour recurrence. Central to this approach are the company’s proprietary Synthetic Super Enhancers (SSEs), which target the unique identity of diseased cell states rather than individual genes. SSEs control two key payloads: a cytotoxic prodrug-converting enzyme and an immune-stimulating cytokine. Using the Odysseus® platform, Trogenix identifies and optimizes targets to rapidly generate clinically viable candidates for preclinical development.

The company’s lead programme in glioblastoma (GBM) is moving toward clinical trials, with first patient dosing expected in Q1 2026. GBM is an aggressive, treatment-resistant brain cancer with only 25 percent of patients surviving beyond one year, and current treatment options remain severely limited. The follow-on programme focuses on colorectal cancer liver metastases (CRCLM), affecting at least 25 percent of colorectal cancer patients, the third most common cancer globally. Beyond these programmes, Trogenix is developing therapies for other aggressive solid cancers, including hepatocellular carcinoma and non-small cell lung carcinoma, reinforcing its commitment to transforming cancer treatment through precision, curative approaches.